Results 51 to 60 of about 8,230,812 (271)

Procedural Volume and Outcomes in Lower‐Extremity Peripheral Vascular Interventions: Insights From the NCDR Peripheral Vascular Intervention Registry

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Lower‐extremity peripheral vascular interventions (PVIs) are increasingly used for treatment of peripheral artery disease. However, the relationship between hospital and operator PVI volume with in‐hospital major adverse limb events (MALEs ...
Zainali Chunawala, Arman Qamar, Kevin Kennedy, Neil Keshvani, Ambarish Pandey, Dharam J. Kumbhani, Cheong Jun Lee, Gregory Mishkel, Eric Secemsky, Deepak L. Bhatt   +9 more
doaj   +1 more source

Major Adverse Cardiovascular Events and Mortality in Systemic Lupus Erythematosus Patients After Successful Delivery: A Population-based Study

, 2017
Background:Limited data exist regarding the incidence rate and hazard ratios (HRs) of major adverse cardiovascular events and mortality in the successful-delivery women with or without systemic lupus erythematosus.Methods:A retrospective, population ...
Wu, Lung-Sheng;Tang, Chao-Hsiun;Lin, Yu-Sheng;Lin, Chia-Pin;Hung, Sheng-Tzu;Hwa, Hsiao-Lin;Luo, Shue-Fen;Chu, Pao-Hsien, 華筱玲   +1 more
core   +1 more source

Prognostic Impact of Interleukin-27 in Peripheral Artery Disease

Life
Atherosclerosis is a progressive arterial disease characterized by chronic inflammation, with interleukin-27 (IL-27) implicated as both a pro- and anti-inflammatory cytokine. This prospective cohort study evaluated association of circulating IL-27 levels
Nataša Kokalj, Borut Jug
doaj   +1 more source

Baseline characteristics according to major adverse cardiovascular events.

, 2021
Baseline characteristics according to major adverse cardiovascular events.
Joo-Hee Zo (721373), Jae-Bin Seo (721370), Myung-A Kim (721372), Woo-Hyun Lim (6157328), Hack-Lyoung Kim (654343), Sang-Hyun Kim (282188), Inki Moon (8293041)   +6 more
core   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective There are limited real‐world data regarding the safety and effectiveness of onasemnogene abeparvovec (OA; Zolgensma) infusion, a one‐time gene replacement therapy, for Japanese patients with spinal muscular atrophy (SMA). We aimed to improve understanding of the real‐world outcomes for OA in Japan.
Kayoko Saito, Kamal Benguerba, Ken Tsuchida, Kazushige Yazawa, Isao Tsumiyama, Hiromitsu Kayama, Sandra P. Reyna, Farid Khan, Richard S. Finkel   +8 more
wiley   +1 more source

Major Adverse Events.

, 2013
Major Adverse Events.
Thomas F. Lüscher (126194), Nazmi Krasniqi (324395), Michael Turgut (324396), Roberto Corti (247492), Urs Schwarz (324398), Beatrice Amann (324400), Marco Roffi (324397), Matthias Greutmann (324399), Marc Husmann (126186)   +8 more
core   +1 more source

Cognitive and Neuroimaging Divergence Between Juvenile and Adult FUS Amyotrophic Lateral Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive motor neuron degeneration. Fused in sarcoma (FUS)‐associated juvenile ALS (jALS) represents a distinct and aggressive subgroup with rapid deterioration and poor prognosis.
Alexandra V. Jürs, Marcel Naumann, Annaliis Lehto, Hanna Schön, Jens Kurth, Johannes Prudlo, Andreas Hermann, Elisabeth Kasper   +7 more
wiley   +1 more source

Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial

Drugs in Context, 2020
Patients with peripheral artery disease (PAD) are at a high risk not only for the classical cardiovascular (CV) outcomes (major adverse cardiovascular events; MACE) but also for vascular limb events (major adverse limb events; MALE).
José Luis Hernández, Francisco S Lozano, Vincent Riambau, Manuel Almendro-Delia, Juan Cosín-Sales, Sergi Bellmunt-Montoya, Javier Garcia-Alegria, Xavier Garcia-Moll, Juan José Gomez-Doblas, José R Gonzalez-Juanatey, Carmen Suarez Fernández   +10 more
doaj   +1 more source

Major Adverse Limb Events and 1-Year Outcomes After Peripheral Artery Revascularization

Journal of the American College of Cardiology, 2018
Revascularization is important for symptom treatment and limb salvage in peripheral artery disease, yet little data exist on the incidence of post-procedure major adverse limb events (MALE) and longer-term outcomes.This study sought to characterize hospitalizations and outpatient endovascular revascularizations after peripheral artery revascularization,
Connie N, Hess, R Kevin, Rogers, Tracy Y, Wang, Rao, Fu, Jacob, Gundrum, Nancy M, Allen LaPointe, William R, Hiatt   +6 more
openaire   +2 more sources